Here are six thoughts:
1. Forty-four of the 431 patients in the mupirocin/chlorhexidine group died after three years.
2. Forty-three of the 362 patients in the placebo group died.
3. Researchers did not detect morality rate differences between the groups based on surgery.
4. In the clean procedures patient group, mupirocin/chlorhexidine decreased one-year mortality.
5. The study found S. aureus carriage detection and decolonization prevents S. aureus surgical-site infections and decreased one-year mortality in patients receiving clean procedures.
6. Researchers suggested the screen-and-treat strategy’s main target should be patients with high-risks of developing S. aureus infections.
More articles on quality:
Healthmark adds Cool Aids Single-Use Vest for healthcare staff: 5 key notes
CDC launches new “Clean Hands Count” campaign: 4 notes
The Joint Commission changes stance, allows providers to text patient care orders: 6 highlights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.